Immutep Ltd (ASX: IMM) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Immutep Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $443.05 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 1.45 billion
Earnings per share -0.039
Dividend per share N/A
Year To Date Return -13.70%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Immutep Ltd (ASX: IMM)
    Latest News

    Shot of a young scientist using a digital tablet while working in a lab.
    Healthcare Shares

    Guess which ASX healthcare stock is surging on big FDA news

    The update is a critical milestone for the company.

    Read more »

    A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
    Share Gainers

    Why 29Metals, Immutep, Insignia, and Perenti shares are pushing higher today

    These shares are avoiding the market selloff. But why?

    Read more »

    Woman looks amazed and shocked as she looks at her laptop.
    Share Gainers

    Why Immutep, Kingsgate, Netwealth, and Ora Banda shares are storming higher

    These shares are ending the week with a bang. But why?

    Read more »

    A woman jumps for joy with a rocket drawn on the wall behind her.
    Healthcare Shares

    Why is this ASX healthcare stock rocketing 25% on Friday?

    What is getting investors excited? Let's find out.

    Read more »

    A man sees some good news on his phone and gives a little cheer.
    Share Gainers

    Why Coronado Global, EML, Immutep, and Lendlease shares are storming higher

    These shares are starting the week strongly. But why?

    Read more »

    Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
    Healthcare Shares

    'Obvious buying opportunity': Top broker says beaten-up ASX All Ords stock has 253% upside

    Wilsons analysts say the market has misread top-line medical trial results released this week.

    Read more »

    Three guys in shirts and ties give the thumbs down.
    Share Fallers

    Why Abacus, Bannerman Energy, Immutep, and Pilbara Minerals shares are falling today

    These shares are having a tough finish to the week. But why?

    Read more »

    A woman looks distressed as she stares dramatically at her phone
    Share Fallers

    Why APA Group, Immutep, NAB, and Immutep shares are sinking

    These shares are having a difficult time on Thursday. What's happening?

    Read more »

    A man slumps crankily over his morning coffee as it pours with rain outside.
    Healthcare Shares

    Why did this ASX healthcare stock just crash 47%?

    Investors have seen something they don't like in a big announcement.

    Read more »

    A woman jumps for joy with a rocket drawn on the wall behind her.
    Broker Notes

    This speculative ASX stock could almost double in value

    Bell Potter thinks investors could almost double their money with this high risk option.

    Read more »

    Close up of a sad young woman reading about declining share price on her phone.
    Share Fallers

    Why Brainchip, Immutep, Liontown, and Xero shares are tumbling today

    These shares are having a tough time on hump day. Why are they falling?

    Read more »

    Five young people sit in a row having fun and interacting with their mobile phones.
    Broker Notes

    These ASX stocks could rise 30% to 85%

    A leading broker has put buy ratings on these shares this morning.

    Read more »

    Frequently Asked Questions

    No, Immutep does not pay dividends at this time.

    Immutep Ltd listed on the ASX on 23 June 1988.

    IMM ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Immutep Ltd

    Immutep Ltd (ASX: IMM) is a biotechnology company developing immunotherapy products for cancer and autoimmune diseases. The company describes itself as a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Immutep's LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune diseases. Immutep currently has three clinical-stage candidates and two earlier-stage candidates.

    IMM Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    23 Jul 2024 $0.31 $0.01 3.39% 6,080,182 $0.30 $0.31 $0.30
    22 Jul 2024 $0.30 $0.00 0.00% 2,454,789 $0.30 $0.31 $0.29
    19 Jul 2024 $0.30 $0.01 3.45% 1,579,437 $0.29 $0.31 $0.29
    18 Jul 2024 $0.29 $-0.01 -3.39% 2,557,191 $0.30 $0.30 $0.29
    17 Jul 2024 $0.30 $-0.01 -3.33% 4,421,595 $0.31 $0.31 $0.29
    16 Jul 2024 $0.30 $-0.02 -6.25% 7,796,353 $0.32 $0.32 $0.30
    15 Jul 2024 $0.32 $-0.04 -11.27% 8,841,271 $0.34 $0.35 $0.32
    12 Jul 2024 $0.36 $0.06 20.34% 18,032,960 $0.36 $0.38 $0.34
    11 Jul 2024 $0.30 $0.01 3.45% 1,834,127 $0.29 $0.30 $0.29
    10 Jul 2024 $0.29 $-0.01 -3.33% 2,589,590 $0.30 $0.30 $0.29
    09 Jul 2024 $0.30 $0.01 3.39% 2,003,070 $0.30 $0.31 $0.30
    08 Jul 2024 $0.30 $0.00 0.00% 2,430,312 $0.30 $0.31 $0.29
    05 Jul 2024 $0.30 $0.02 7.14% 2,824,118 $0.29 $0.31 $0.28
    04 Jul 2024 $0.28 $0.00 0.00% 4,777,157 $0.29 $0.29 $0.28
    03 Jul 2024 $0.29 $-0.01 -3.45% 5,001,735 $0.29 $0.30 $0.28
    02 Jul 2024 $0.29 $-0.02 -6.45% 7,109,867 $0.32 $0.32 $0.28
    01 Jul 2024 $0.31 $0.02 6.78% 7,793,411 $0.32 $0.35 $0.31
    28 Jun 2024 $0.30 $-0.04 -11.94% 23,750,495 $0.32 $0.33 $0.28
    27 Jun 2024 $0.34 $-0.10 -22.99% 50,198,070 $0.39 $0.40 $0.23
    26 Jun 2024 $0.44 $0.02 4.76% 3,301,068 $0.42 $0.44 $0.42
    25 Jun 2024 $0.42 $0.00 0.00% 2,721,557 $0.42 $0.43 $0.41

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    23 Nov 2023 Russell Howard Issued 178,356 $52,615
    Director remuneration. 404,770 Director Performance Rights
    23 Nov 2023 Lis (Elisabeth) Boyce Issued 589,955 $174,036
    Director remuneration. 589,955 Director Performance
    Rights
    03 Oct 2023 Pete Meyers Exercise 500,000 $142,500
    Conversion of securities. 1,166,667 Performance Rights
    03 Oct 2023 Pete Meyers Issued 500,000 $142,500
    Conversion of securities.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Russell J Howard Non-Executive ChairmanNon-Executive Director May 2013
    Dr Howard is an Australian scientist, executive manager, and entrepreneur. He was a pioneer in molecular parasitology and commercialisation of DNA Shuffling. He is an inventor of 9 patents and has over 140 scientific publications. After his PhD in biochemistry from the University of Melbourne, he held positions at several research laboratories, including the National Institutes of Health in the USA where he gained tenure. In industry, Dr Howard worked at Schering Plough's DNAX Research Institute in Palo Alto, CA; was the President and Scientific Director of Affymax, Inc. and co-founder and CEO of Maxygen, Inc.
    Ms Anne L Anderson Non-Executive Director Feb 2024
    Ms Anderson has board and leadership experience serving Australian and international companies. Anne currently serves as NED of leading Australian wealth manager, BTFM and was previously on the Board of an unlisted subsidiary of Ingenia Communities Group. She currently holds a portfolio of advisory and committee roles including as a Member of the Advisory Board to The Treasury (Australia), Member of the EnergyCo Transmission Acceleration Facility Investment Committee for the NSW Treasury, Advisor to the REST Board Investment Committee, Independent Member of the Minderoo Foundation and E&P Financial Group Investment Committees and Member of the ASIC Consultative Panel. Prior to her NED and committee roles, she completed an executive career of more than 35 years spanning the energy and global financial services sectors.
    Mr Pete A Meyers Non-Executive Deputy ChairmanNon-Executive Director Feb 2014
    Mr Meyers is the Chief Financial Officer of Slayback Pharma LLC. Prior to joining Slayback, Mr Meyers served in Chief Financial Officer roles at Eagle Pharmaceuticals, Inc., Motif BioSciences Inc. and TetraLogic Pharmaceuticals Corporation. Prior to his role at TetraLogic, Mr Meyers spent 18 years in health care investment banking, holding positions of increasing responsibility at Dillon, Read &Co., Credit Suisse First Boston LLC.
    Mr Marc Voigt Chief Financial OfficerChief Executive OfficerExecutive Director May 2012
    Mr Voigt has more than 21 years of experience in the financial and biotech industry, having joined the Immutep team in 2011 as the General Manager, European Operations based in Berlin, Germany. In May 2012, he became Immutep 's Chief Business Officer and in November 2012 its Chief Financial Officer, as well as continuing to focus on its European operations. Having started his career at the Allianz Group working in pension insurances and funds, he moved to net.IPO AG, a publicly listed boutique investment bank in Frankfurt where he was focused on IPOs and venture capital investments.
    Professor Frederic Triebel Executive Director Sep 2022
    Professor Triebel founded Immutep S.A. in 2001 to develop LAG-3 product candidates as human medicines and became Chief Medical Officer and Chief Scientific Officer of Immutep following the Company's acquisition of Immutep S.A in December 2014. While working at IGR as an oncologist, he was also a Professor in Immunology at Paris University and a Director of an INSERM Unit from 1991 to 1996.
    Ms Lis (Elisabeth) Boyce Non-Executive Director Apr 2023
    Ms Boyce is corporate lawyer. She is currently a partner at Piper Alderman and was previously a partner at Dentons, having been at DibbsBarker for nearly 30 years. She has involvement in the Life Sciences and Healthcare sectors and is currently deputy chair of AusBiotechs AusMedtech Advisory Group and a member of AusBiotechs NSW Leadership Committee.
    Ms Deanne Miller Chief Operating OfficerCompany SecretaryGeneral Counsel
    -
    Ms Indira Naidu Joint Company Secretary Jan 2021
    -
    Deanne Miller Chief Operating OfficerCompany SecretaryGeneral Counsel
    -
    Indira Naidu Joint Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 386,571,289 32.56%
    J P Morgan Nominees Australia Pty Limited 165,050,307 13.90%
    Citicorp Nominees Pty Limited 81,121,672 6.83%
    Tripp Investments Pty Ltd <Tripp Investment A/C> 70,936,692 5.97%
    Tekkorp Holdings Llc 39,284,648 3.31%
    National Nominees Limited 11,243,351 0.95%
    Bnp Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> 11,191,695 0.94%
    Edinburgh Park Stud Pty Ltd 8,653,764 0.73%
    Todd Cameron Buckingham 7,692,440 0.65%
    Rbw Nominees Pty Ltd <Rbw Discretionary A/C> 7,584,327 0.64%
    Mr David Mark Rocci 6,862,905 0.58%
    Bridgetrack Investments Pty Ltd 6,484,177 0.55%
    Revilo Corporate Pty Ltd <Revilo Corporate A/C> 6,053,816 0.51%
    Tjct Pty Limited <Buckingham Super Fund A/C> 4,978,772 0.42%
    P G Binet (No 5) Pty Ltd 4,799,700 0.40%
    J & M Hunter Investments Pty Ltd <J & M Hunter Investment A/C> 4,114,620 0.35%
    Ada Services (Nsw) Pty Ltd <Ada Services Super Fund A/C> 3,800,000 0.32%
    Hawksburn Capital Pte Ltd <Methuselah Strategic Fnd A/C> 3,267,305 0.28%
    Christopher Robert Begg 3,074,592 0.26%
    Mr Karl Alexander Begg 2,774,395 0.23%

    Profile

    since

    Note